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Abstract: Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and affects over 6 mil-
lion people worldwide. Development of new drugs to treat this disease remains a priority since those
currently available have variable efficacy and frequent adverse effects, especially during the long regi-
mens required for treating the chronic stage of the disease. T. cruzi modulates the host cell-metabolism
to accommodate the cell cytosol into a favorable growth environment and acquire nutrients for its
multiplication. In this study we evaluated the specific anti-T. cruzi activity of nine bio-energetic
modulator compounds. Notably, we identified that 17-DMAG, which targets the ATP-binding site
of heat shock protein 90 (Hsp90), has a very high (sub-micromolar range) selective inhibition of
the parasite growth. This inhibitory effect was also highly potent (IC50 = 0.27 µmol L−1) against
the amastigote intracellular replicative stage of the parasite. Moreover, molecular docking results
suggest that 17-DMAG may bind T. cruzi Hsp90 homologue Hsp83 with good affinity. Evaluation in
a mouse model of chronic T. cruzi infection did not show parasite growth inhibition, highlighting the
difficulties encountered when going from in vitro assays onto preclinical drug developmental stages.
Keywords: Trypanosoma cruzi; Chagas disease; metabolism drugs; phenotypic assays; cytotoxicity
assays; chronic in vivo model; dorsomorphin; 17-DMAG
1. Introduction
Chagas disease (or American Trypanosomiasis) is caused by the protozoan parasite
Trypanosoma cruzi (T. cruzi). The disease was discovered more than 110 years ago, but
it remains an important public health issue in Latin America. Moreover, the number of
detected cases in nonendemic regions of Northern America and Europe has increased due
to population movements during the last decades. Nowadays, it is estimated that over
6 million people are affected by the disease which causes more than 10,000 deaths per
year [1].
T. cruzi infection clinically progresses in two well differentiated stages. First there
is a short acute phase (4–8 weeks long) that is mostly asymptomatic and thus frequently
undiagnosed and untreated. After these initial stages, the parasite enters into a persistent
and long-lasting chronic phase that may remain asymptomatic or cause cardiac and/or
digestive tissue damage in approximately 30% of patients, leading to years of disability
and eventually death if left untreated [2,3].
Currently, there are two antiparasitic drugs available to treat T. cruzi infections: ben-
znidazole (BNZ) and nifurtimox (NFX) [1]. Both are nitroheterocyclic derivatives with
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high efficacy against the acute stage of the infection. However, efficacy diminishes for
both drugs against the chronic stage, which is when diagnosis is usually obtained [4]. The
long term administration regimes to treat the disease have frequent side effects and results
in low adherence to treatment [4–7]. Additionally, drug resistance has been observed in
some discrete typing units (DTUs) [8], and no vaccine or chemo-prophylactic agents are
available. Therefore, identification of safer and more efficacious drugs to treat the chronic
stage of the infection is urgently needed [9].
Drugs targeting fundamental enzymes or metabolic pathways in the host cell could
be a source of potential antiparasitic treatments, since metabolic coupling of intracellular
pathogens with host cells is essential for successful colonization of the host [10]. In this
respect, Caradonna and coworkers described that host metabolic networks of energy
production, nucleotide metabolism, pteridine biosynthesis, and fatty acid oxidation are
important for intracellular T. cruzi growth, providing experimental proof of the bond
between host cells metabolic states and parasite development [10]. It was observed that
host cells Coenzyme Q10 production was linked to pyrimidine biosynthesis and T. cruzi
amastigotes replication [10]. Additionally, the serine/threonine kinase AKT, involved in
the regulation of multiple cell proliferation and survival pathways, was identified as an
important regulator of amastigotes replication, despite the mechanistic basis of its influence
is yet unknown [10]. In general, a metabolic environment favoring fatty acid oxidation
over glucose oxidation seemed to benefit intracellular amastigotes growth [10]. Similarly, T.
cruzi replication was favored when cells maintained high ATP/ADP ratios, which could be
induced by the inactivation of 5’-AMP-activated protein kinase (AMPK). AMPK controls
cell energy homeostasis, inducing the switch between anabolic and catabolic pathways
when ATP/ADP ratios are unbalanced [11].
In the search of novel chemical entities for Chagas disease, we evaluated a collec-
tion of compounds (AICAR, dorsomorphin, SC79, Akti-1/2, oligomycin, etomoxir, and
17-DMAG) and two licensed drugs (doxycycline and sodium salicylate), which target
key metabolic enzymes modulating bioenergetic cellular pathways (Figure 1; chemical
structures in Figure S1). AMPK is modulated positively by AICAR and sodium salicylate
and negatively by dorsomorphin [12], while AKT is activated by SC79 and inhibited by
Akti-1/2 [13]. Oligomycin and etomoxir have been, respectively, described to inhibit the
mitochondrial ATP synthase and the carnitine palmitoyltranferase-1 (CPT-1). By inhibiting
ATP synthase, oligomycin promotes the induction of glucose uptake through AMPK and
AKT dual pathways, avoiding at the same time the intracellular uptake of calcium ions [14].
Despite its acknowledged toxicity we decided to include it as an inhibitor of mitochondria
function. On the other side, etomoxir mediated inhibition of CPT-1 inhibits fatty acids
oxidation [15]. Compound 17-DMAG was reported to inhibit the activity of the heat shock
protein 90 (Hsp90) leading to protein misfolding and ubiquitin-dependent proteasome
degradation [16]. It has also been described to antagonize hypoxia-inducible factor 1 alpha
(HIF1α), a transcription factor that controls energy metabolism and angiogenesis under
hypoxic conditions [17]. Doxycycline is a broad-spectrum antibiotic of the tetracycline fam-
ily applied to the treatment of bacterial pneumonia, acne, early Lyme disease, gonorrhea,
typhus, and syphilis [18]. It impairs synthesis of proteins encoded in the mitochondrial
genome and changes gene expression patterns shifting metabolism towards a more gly-
colytic phenotype in human cells [19]. While the other licensed drug, sodium salicylate,
activates AMPK, central regulator of cell growth and metabolism [20].
Herein, we explored whether aforementioned bioenergetic modulators specifically
inhibited T. cruzi growth by means of antiparasitic and cell toxicity in vitro phenotypic
assays. Binding of the most active one, 17-DMAG, to its main enzymatic target was further
analyzed in silico. Ultimately, encouraged by retrieved results, 17-DMAG activity was also
evaluated in an in vivo model of chronic T. cruzi infection.
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Figure 1. Host Cell Metabolic Routes Scheme. It shows known targets and effects on them of the compounds evaluated in 
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Compound activity against T. cruzi mammalian stages was determined using a 
phenotypic assay based on African green monkey kidney epithelial cells (Vero, ATCC® 
CCL-81™) infected with an engineered T. cruzi—Tulahuen strain (DTU VI) expressing 
beta-galactosidase [21,22]. In every run of the assay we included the reference drug BNZ 
as control. This had an average IC50 value of 1.63 (0.11) μmol L−1 (Figure 2) which is sim-
ilar to previous reports [22,23]. 
Upon evaluating the nine compounds in at least three independent experiments, six 
of them were found to be inactive against the parasite (AICAR, SC79, Akti-1/2, etomoxir, 
sodium salicylate, and doxycycline; Table S1). In contrast, dorsomorphin, oligomycin, 
and 17-DMAG showed a T. cruzi growth inhibition activity more potent than that of the 
reference drug BNZ (Figure 2 and Figure S2). Respectively, dorsomorphin, oligomycin, 
and 17-DMAG yielded average IC50 values of 0.24 (0.021) μmol L−1, 0.52 (0.047) μmol L-1, 
and 0.017 (0.001) μmol L−1 (Table 1). 
Figure 1. Host Cell Metabolic Routes Scheme. It shows known targets and effects on them of the compounds evaluated in
this work. (Figure created with Biorender.com).
2. Results
2.1. Anti-T. cruzi Activity
Compound activity against T. cruzi mammalian stages was determined using a phe-
notypic assay based on Africa green monkey kid ey epithelial cells (Vero, ATCC® CCL-
81™) infected with an engineered T. cruzi— ulahuen str in (DTU VI) expressing beta-
galactosid se [21,22]. In every run of the assay we included the referenc d ug BNZ as
control. This had an average IC50 value of 1.63 (0. 1) µmol L−1 (Figure 2) which is s milar
to previous ports [22,23].
Upon evaluating the nine compounds in at le st three independ t experiments, six
of them were found to be inactive against the parasite (AIC R, SC79, Akti-1/2, etomoxir,
sodium salicylate, nd doxycycline; Table S1). In co trast, dorsomorphin, olig mycin,
and 17-DMAG showed a T. cruzi growth in ibition activity more potent than that of he
refe nce drug BNZ (Figure 2 and Figure S2). Respectively, dorsomorphin, olig mycin,
and 17-DMAG yielded aver ge IC50 values of 0.24 (0.021) µmol L−1, 0.52 (0.047) µmol L−1,
and 0.017 (0.001) µmol L−1 (Table 1).
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Figure 2. Anti-Trypanosoma cruzi Assay Dose–Response Curves. Graphs represent mean results and standard deviation 
(SD) of at least three independent biological replicas. 
Table 1. Table Displaying the Averaged IC50, TC50, and SI Values Obtained in the Study. 
Compound IC50 IC50 a 
AlamarBlue Assay Crystal Violet Assay 
TC50 SI SI a TC50 SI SI a 
BNZ 1.63 2.02 243.8 149.6 120.6 140.2 86.0 69.4 
Dorsomorphin 0.24 N.T. 16.6 69.2 - 0.26 1.2 - 
17-DMAG 0.017 0.27 6.23 366.5 23.1 2.97 174.7 11.0 
IC50 and TC50 values are, respectively, defined as the compound concentration that inhibits parasite growth by 50% or is 
toxic to 50% of cells. SI stands for selectivity index and is determined by the rate between TC50 and IC50 values. a, 
Antiamastigote assay; all IC50 and TC50 values are shown as μmol L−1; N.T., not tested. 
2.2. Identification of Compounds with Specific Activity Against the Parasite 
A secondary cell toxicity assay with monkey Vero cells was performed to test for 
parasite specificity of dorsomorphin and 17-DMAG compared to host cells. Oligomycin 
was discarded from further evaluation because it is highly toxic to human subjects [24]. 
Since compounds under study were metabolic inhibitors, we evaluated their impact 
on host cells viability with two different methodologies: AlamarBlue and crystal violet 
assays (see Section 4.5 for details). BNZ, included as reference in the Vero toxicity assays, 
yielded an average TC50 value of 243.8 (17.04) μmol L−1 in the AlamarBlue-based assay 
and 140.2 (13.18) μmol L−1 in the crystal violet assay as reported (Table 1, Figure S3) 
[22,23]. In order to consider any of the two compounds suitable for further progression 
Figure 2. Anti-Trypanosoma cruzi Assay Dose–Response Curves. Graphs represent mean results and standard deviation (SD)
of at least three independent biological replicas.
Table 1. Table Displaying the Averaged IC50, TC50, and SI Values Obtained in the Study.
Compound IC50 IC50 a
AlamarBlue Assay Crystal Violet Assay
TC50 SI SI a TC50 SI SI a
BNZ 1.63 2.02 243.8 149.6 120.6 140.2 86.0 69.4
Dorsomorphin 0.24 N.T. 16.6 69.2 - 0.26 1.2 -
17-DMAG 0. 17 0.27 6.23 366.5 23.1 2.97 174.7 11.0
IC50 and TC50 values are, respectively, defined as the compound concentration that inhibits parasite growth by 50% or is toxic to 50% of
cells. SI stands for selectivity index and is determined by the rate between TC50 and IC50 values. a, Antiamastigote assay; all IC50 and TC50
values are shown as µmol L−1; N.T., not tested.
2.2. Identification of Compounds with Specific Activity against the Parasite
A secondary cell toxicity assay with monkey Vero cells was performed to test for
parasite specificity of dorsomorphin and 17-DMAG compared to host cells. Oligomycin
was discarded from further evaluation because it is highly toxic to human subjects [24].
Since compounds under study were metabolic inhibitors, we evaluated their impact on
host cells viability with two differ nt methodologies: AlamarBlue and crystal violet assays
(see Section 4.5 for details). BNZ, included as refere ce in he Vero toxicity assay , yielded
an average TC50 value of 243.8 (17.04) µmol L−1 in the AlamarBlue-based assay and 140.2
(13.18) µmol L−1 in the crystal violet assay as reported (Table 1, Figure S3) [22,23]. In order
to consider any of the two compounds suitable for further progression we determined a
selectivity index (SI, i.e., the ratio between TC50 and IC50) > 10 in both readouts. Such SI
ratio is commonly used to consider compounds with specific antiparasitic activity [25].
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Vero cells toxicity of dorsomorphin in the AlamarBlue fluorescent-based readout
[TC50 = 16.6 (1.88) µmol L−1] indicated that its activity against the parasite was specific
(SI = 69.2; Table 1, Figure 3). However, the colorimetric readout revealed a higher toxicity
profile for Vero [TC50 = 0.26 (0.032) µmol L−1] which resulted in a SI value < 10 (Table 1,
Figure 3).
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17-DMAG had an average TC50 value of 6.23 (0.86) µmol L−1 against Vero cells in
the AlamarBlue assay (SI = 366.5; Table 1, Figure 3). Then, although crystal violet readout
resulted again in higher toxicity [TC50 = 2.97 (0.37) µ ol L−1] (Table 1, Figure 3), its SI
prevailed > 10 (SI = 174.7). In fact, 17-DMAG showed wider selectivity indexes than those
obtained with the reference drug BNZ (Table 1).
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2.4. Hsp90 Is the Target of 17-DMAG
We further inquired if the observed antiparasitic effect of 17-DMAG could be related
to the inhibition of the mammalian Hsp90 or if the compound could also be targeting
T. cruzi Hsp90 homologue Hsp83 [26]. Previous studies have described that 17-DMAG
binds with higher affinity to the N-terminal domain of Hsp83 proteins from T. cruzi close
relatives Trypanosoma brucei and Leishmania amazonensis, as well as to that of Plasmodium
falciparum in comparison to human Hsp90 [27–30]. Multiple sequence alignment showed a
high percentage of identity (>60%) between human Hsp90 and its parasite homologues [31]
(Figure S4). Particularly, identity of N-term domains, where the ATP-binding pocket is
located, was 73% between human Hsp90 and T. cruzi Hsp83 (Figure S4).
Since the 3D structure of human Hsp90 bound to 17-DMAG is available [32], we
performed a morphological analysis of the interaction between this compound and T.
cruzi Hsp83 protein with PyMol [33]. It revealed a different surface conformation of
the ATP-binding pocket between both chaperones (Figure 5). Alignment-driven in silico
mutagenesis entailed substituting human Hsp90 lysine (K) 112 for an arginine (R) 97
residue in T. cruzi Hsp83. In Hsp90 protein, the amine group of L112 forms a hydrogen
bond of 3 Å with the C-18 ketone of 17-DMAG [32]. In contrast, the two amine groups of
R97 in T. cruzi Hsp83 would interact with the C-18 ketone upon the formation of two bonds
of 2.8 and 2.9 Å (Figure 5). Substitution of isoleucine (I) 91 onto a valine (V) did not seem
to affect the water-mediated interaction.
In addition to the visualization of 17-DMAG interaction with the ATP-binding pockets
of Hsp90 and Hsp83, we evaluated the binding affinity of 17-DMAG to both chaperones
with Vina Wizard software [34]. This analysis predicted a free energy value of−9.7 Kcal/mol
for the binding of 17-DMAG to Hsp90, whereas it was −6.2 Kcal/mol for T. cruzi Hsp83.
2.5. In Vivo Anti-T. cruzi Activity of 17-DMAG in a Mouse Model of Chronic Infection
Ultimately, antiparasitic activity of 17-DMAG was assessed in an in vivo model of
chronic T. cruzi infection with a transgenic parasite expressing luciferase (Brazil strain, DTU
I) [35,36]. In this assay, the signal provided by luciferase after injection of its substrate in the
animals is proportional to the T. cruzi load, and it is considered a surrogate for parasitemia.
Infected mice reached the peak of parasitemia at day 23 and treatment started at day 132
once chronic infection had been established (Figure 6A). One experimental group was
treated intraperitoneally with 30 mg/kg/day of 17-DMAG for five days (Figure 6A,B),
while other was treated five times every three days (over a 15 days period) with same
dose (Figure 6A,C). We used these dosage and regimes following previous works by
Meyer and coworkers and Santos and coworkers, respectively [37,38]. Vehicle-treated and
BNZ-treated groups (same regimes and dose: 30 mg/kg/day) were included as controls.
None of the groups treated with 17-DMAG showed statistically significant differences
versus either vehicle or BNZ groups. Similarly, no statistically significant differences in the
registered luciferase signal were observed between daily or intermittently treated mice,
either with 17-DMAG or BNZ (data not shown). After treatment, mice treated daily and
those treated intermittently with 17-DMAG, respectively had mean luminescence values
(AU) of 1.95 × 106 (±5.60 × 105) and 8.69 × 106 (±1.27 × 107) photons s−1. Such values
were higher than the 5 × 105 photons s−1 threshold indicative of parasite clearance that
had been determined by imaging a noninfected mouse injected with luciferase substrate
the same as infected [39].
Int. J. Mol. Sci. 2021, 22, 688 7 of 16




Figure 5. Binding of 17-DMAG to Human Hsp90 and T. cruzi Hsp83. (A) Binding pocket surface of 
Hsp90 (left) and Hsp83 (right) with 17-DMAG. (B) Zoom-in to the residue interactions of Hsp90 
(left) and Hsp83 (right) with 17-DMAG. (C) Zoom-in to the K112 residue of Hsp90 (left) and R97 
residue of Hsp83 (right) interaction with 17-DMAG. PyMol software was used for visualizing PDB 
ref.: 1OSF [32]. 17-DMAG structure is represented in green and protein structure in grey. In panel 
A, arrows indicate morphological differences between both surfaces. In panel C, arrows show the 
position of expected H-bonds between 17-DMAG and K112 or R97 residues, respectively. Hsp90/83 
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Figure 5. Binding of 17-DMAG to Human Hsp90 and T. cruzi Hsp83. (A) Binding pocket surface of
Hsp90 (left) and Hsp83 (right) with 17-DMAG. (B) Zoom-in to the residue interactions of Hsp90
(left) and Hsp83 (right) with 17-DMAG. (C) Zoom-in to the K112 residue of Hsp90 (left) and R97
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ref.: 1OSF [32]. 17-DMAG structure is represented in gr en and protein structure in grey. In panel
A, arrows indicate morphological differences between both surfaces. In panel C, arrows show the
position of expected H-bonds between 17-DMAG and K112 or R97 residues, respectively. Hsp90/83
from panel B is represented as cartoons; in panel C they are represented as sticks [33].
At the dose used (30 mg/kg/day), BNZ did not manage to completely clear the
infection. Nonetheless, in the group of animals that received the drug intermittently over
15 days, there was a 6-fold significant reduction of parasitemia after treatment (p < 0.01,
comparing levels at days 132 and 14 ) (Figure 6C). Finally, it must be noted that mice under
the 17-DMAG daily regime showed signs of treatment associated toxicity. These were not
observed in the animals that were intermittently treated with the compound. None of the
animals treated with BNZ showed signs of drug-associated toxicity.
Int. J. Mol. Sci. 2021, 22, 688 8 of 16
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107) photons s−1. Such values were higher than the 5 × 105 photons s−1 threshold indicative 
of parasite clearance that had been determined by imaging a noninfected mouse injected 
with luciferase substrate the same as infected [39]. 
 
Figure 6. In vivo model of chronic T. cruzi infection. (A) Experimental timeline of events. Blue squares refer to experimental
groups treated daily for five days whereas green squares to groups treated five times over 15 days. (B) Parasitemia evolution
represented by graphs and images of animals treated daily for five days. (C) Parasitemia evolution represented by graphs
and images of animals treated five times over 15 days. The luminescence reactivity shown longitudinally in panels B and C
are mean and SD values of all the mice within each corresponding group.
3. Discussion
Out of the nine metabolic inhibitors evaluated, three showed a highly potent antipara-
sitic activity: dorsomorphin, 17-DMAG, and oligomycin. The latter was included to test
that a functional host cell mitochondria was important for the parasite survival, but it was
discarded from further progression for its reported acute toxicity.
Cell toxicity assessment of the other two active compounds revealed that only 17-
DMAG was specific against the parasite. This was concluded upon performing two
complementary cell toxicity assays with AlamarBlue and crystal violet substrates [40,41],
which measure cell metabolic activity and membrane integrity, respectively. No significant
differences in 17-DMAG TC50 values were recorded, and the fact that toxicity was slightly
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higher in the crystal violet assay might have been due to its distinct readout addressing
membranes integrity.
Dorsomorphin (also known as compound C) was originally identified as an AMPK
inhibitor and widely used in cancer studies [11]. In this study it showed a high antiparasitic
activity in the anti-T. cruzi assay, but it was also shown to be highly toxic against Vero cells
[TC50 = 0.26 (0.032) µmol L−1] in the crystal violet based cell toxicity assay. Flagged as
nonspecific against the parasite, it was discarded from subsequent analysis.
Regarding 17-DMAG, to the best of our knowledge, this is the first time that its
anti-T. cruzi growth inhibition activity has been described. It was highly potent, in the
submicromolar range (IC50 = 17 nmol L−1), in the primary antiparasitic assay. Moreover,
its activity was determined to be parasite specific also in the anti-amastigote assay. That
17-DMAG potency was lower in the latter might be due to amastigotes being less accessible
to it as intracellular forms. Nonetheless, still a strong submicromolar antiparasitic activity
was registered (IC50 = 0.17 µmol L−1).
17-DMAG is a derivative of geldanamycin, which has been reported to inhibit the
activity of the Hsp90 protein family [16], and to antagonize HIF1α transcription factor [17]
(Figure 1). Amongst different Hps90 inhibitors like geldanamycin, 17-AAG or 17-DMAG,
the latter has been chosen in multiple assays due to its potency, selectivity, and better water
solubility [37]. Hsp90 proteins are chaperones modulating availability of client proteins
(kinases and nuclear receptors) thus enabling important cellular processes such as cell
growth, signal transduction, and development [29]. Eukaryotic cells have three types
of Hsp90s: cytosolic Hsp90 with two isoforms (Hsp90α and Hsp90β), Grp94 (glucose-
regulated protein 94) at the endoplasmic reticulum (ER), and the mitochondrial Trap1
(tumor necrosis receptor-associated protein 1) [16]. The sequence of Hsp90 proteins is rather
conserved and its activity has been documented also in intracellular protozoan parasites
such as those within genus Trypanosoma, Leishmania, Toxoplasma, and Plasmodium [37,42].
Three functional domains are found within Hsp90s: a N-term domain with an ATP-binding
site and ATPase activity; a middle region where the binding site for client proteins is located;
and a homo-dimerization domain with another binding site for ATP at their C-term [16]
(Figure 1; Figure S4). Remarkably, structural studies have shown that compound 17-DMAG
binds to the ATP-binding site of the N-term domain [32]. Others have investigated the
use of 17-DMAG against various human pathogens [28,30,37,43]. Palma and coworkers
reported a higher selectivity of 17-DMAG against L. amazonensis cells (IC50 = 86.1 nmol L−1)
than to THP−1 host cells (TC50 = 10.6 µmol L−1) [28]. Similarly, Meyer and coworkers
demonstrated its higher selectivity against T. brucei (IC50 = 3.1 nmol L−1) in comparison
to L1210 mouse cells (TC50 = 1000 nmol L−1) [37], and P. falciparum growth was also
suppressed by 17-DMAG at nontoxic concentrations to the host cells [30]. Notably, in vivo
studies have already shown that 17-DMAG, administered either intraperitoneally or orally
at a supposedly nontoxic dose of 30 mg kg−1 for five days cured mice of a lethal T. brucei
infection decreasing the parasitemia to the limit of detection by day three [37].
Besides, 17-DMAG has successfully reached phase I clinical studies in patients with
advanced solid cancers [44–46] and lymphocytic and myeloid leukemia [47]. The highest
dose reached in these phase I studies without experimenting dose-limiting toxicity was
80 mg/m2, even though lower doses were also defined as effective [45,46]. Most common
adverse events were fatigue, nausea, vomiting, anorexia, gastrointestinal, liver function
changes, and ocular alterations [44,45]. The maximum blood tolerated concentrations
were 600–2700 nmol L−1 [37], which would exceed the 17–270 nmol L−1 IC50 range we
determined against T. cruzi in this work.
T. cruzi Hsp90 homologue Hsp83 participates in the parasite cell cycle by controlling
the differentiation of insect to mammalian infective forms [26]. It has also been described
to have high ATPase activity, particularly stimulated in the presence of peptides [26]. Since
a 73% sequence conservation was observed between N-term of T. cruzi Hsp83 and human
Hsp90 [48], we decided to follow an approach to visualize a hypothetical Hsp83–17-DMAG
interaction. Somewhat, in silico results unveiled a more embracing binding pocket surface
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to 17-DMAG in the modeled T. cruzi Hsp83 in comparison to human Hsp90 (Figure 5).
The model also showed that the unique interaction of 17-DMAG C-18 ketone with human
Hsp90 K112 was substituted by two bonds with T. cruzi Hsp83 R97, which would have an
expected shorter binding distance from 3Å to 2.8 and 2.9 Å, respectively. Such differences
may allow a swifter binding of 17-DMAG to Hsp83 N-term domain. In other related
parasites, Palma and coworkers reported a higher affinity of 17-DMAG to L. amazonensis
Hsp83 than to human Hsp90 based on in vitro assays and docking-structural analysis [28].
Additionally, thermal shift assays showed an affinity up to two-fold higher for T. brucei
Hsp83 than to human Hsp90 [28]. However, the predicted energy required to disrupt
17-DMAG binding to T. cruzi Hsp83 was lower than that predicted for the human Hsp90
(∆G = −6.2 Kcal/mol (−25.9 KJ/mol), versus ∆G = −9.7 Kcal/mol (−40.6 KJ/mol)). This
would indicate a lower binding affinity between 17-DMAG and Hsp83. The predicted
binding affinity value of 17-DMAG to the human Hsp90 correlates with that previously
reported (∆G = −32.3 KJ/mol) [49]. Our Vina Hsp83 model did not take into consideration
the presence of solvent in the interface and the conformational changes that occur during
the complex formation. It has been described that water-mediated hydrogen bonds between
Hsp90 inhibitor compounds and amino acid residues within N-term domain of T. brucei
Hsp83 were important as they simulated the positioning of one of the phosphate groups
of ATP [27]. Furthermore, Nilapwar and coworkers reported the importance of water-
mediated hydrogen bonds by direct bridging or by forming a network of water molecules
in human Hsp90 complex formation with geldanamycin, 17-AAG and 17-DMAG [49], and
it is also known that conformational changes coupled to ligand binding can contribute to
modify the binding affinity [49]. Whether 17-DMAG in vitro antiparasitic effect is due to
an inhibition of the host cells Hsp90 or T. cruzi Hsp83 remains to be elucidated. Moreover,
since 17-DMAG has also been described to inhibit host cell glycolysis route through HIF1α,
a change in the metabolic state of the cells might as well be having an impact in the parasite
intracellular multiplication.
The potent and specific activity of 17-DMAG against T. cruzi in vitro, and its formerly
described in vivo activity against closely related parasites [37,38], prompted its evaluation
in a chronic model of T. cruzi infection. In this, 17-DMAG did not inhibit parasite presence
in the infected mice. We did not observe a statistically significant decrease in parasitemia
in mice treated intraperitoneally with 17-DMAG at 30 mg/kg daily for five days or those
intermittently treated every three days over 15 days (five times in total) in comparison
with vehicle inoculated animals (Figure 6). Neither was that presence eliminated by similar
treatment (dosage and regime) with Chagas disease standard drug BNZ. Nonetheless,
decay in parasitemia was indeed observed in those animals intermittently treated with
BNZ, likely due to longer availability of the drug to act and contribute to reduce parasite
presence. Clearance of T. cruzi parasitemia with BNZ in chronically infected mice has
been described upon administration of ≥100 mg/kg/day over at least 20 days [50–52].
Reason to include a control group of animals treated with 30 mg/kg/day was to parallel
test groups in regime and dose.
Administering 17-DMAG at a higher dose than the one evaluated here may not be
an option in future experiments, at least in its daily administration regime and in this
mouse strain. Among the observed signs of toxicity in mice within daily treated group,
there were lethargy and ruffled fur. Formerly, Meyer and coworkers did not report signs of
toxicity in T. brucei infected mice treated with the same dose [37]. This could be explained
by the use of different mouse strains [53], as well as by the immunological compromise
caused by each parasite when treatment started. Herein reported failure of 17-DMAG in a
chronic in vivo model reminds that of posaconazole, which also presented a very potent
in vitro anti-T. cruzi activity [54]. BNZ and NFX remain as the best possible Chagas disease
treatments at the moment. It will be fundamental to determine whether alternative regimes
currently under clinical evaluation manage to reduce their frequent adverse effects while
maintaining (or increasing) efficacy [9]. Until then, efforts to try to identify a safe and
highly effective therapy should continue.
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4. Materials and Methods
4.1. Collection of Compounds/Drugs
Sodium salicylate (CAS N 54-21-7), oligomycin from Streptomyces diastatochromogenes
(CAS N 1404-19-9) and doxycycline monohydrate (CAS N 17086-28-1) were purchased
from Sigma-Aldrich (St. Louis, MO, USA). 17-DMAG (CAS N150270-08-9) was purchased
from Tebu-bio (Barcelona, Spain). AICAR (CAS N 2627-69-2), Akti-1/2 (CAS N 612847-
09-3), dorsomorphin dihydrochloride (CAS N 1219168-18-9), SC79 (CAS N 305834-79-1),
and (R)-(+)-etomoxir sodium salt (CAS N 828934-41-4) were purchased from TOCRIS
(Bristol, UK).
AICAR, Akti-1/2, dorsomorphin, etomoxir, and SC79 stock dilutions were prepared in
DMSO at 20 mM whereas oligomycin and 17-DMAG were prepared at 2 and 1 mmol L−1,
respectively. The drug sodium salicylate was prepared before use in the appropriate culture
media at a starting concentration of 200 µmol L−1.
4.2. Host Cells Cultures
Vero (green monkey kidney epithelial cells) [55], LLC-MK2 (Rhesus monkey kidney
epithelial cells) [22] were kept with DMEM supplemented with 1% penicillin-streptomycin
(100 units/mL of penicillin and 100 µg/mL of streptomycin; P-S) and 10% heat inactivated
fetal bovine serum (FBS) at 37 ◦C, 5% CO2, and >95% humidity as described [21].
4.3. Culture of T. cruzi Parasites
T. cruzi parasites from the Tulahuen strain (Discrete Typing Unit VI) expressing β-
galactosidase were kindly provided by Dr. Fred Buckner (University of Washington, Seattle,
WA, USA) and maintained using LLC-MK2 cells as hosts in DMEM supplemented with
2% FBS and 1% P-S-G [21]. Free-swimming trypomastigotes were purified as described
to keep the parasite cycle in LLC-MK2 cells and for the performance of the antiparasitic
assays [22].
4.4. Assay to Detect T. cruzi Growth Inhibition in 96-Well Plates
Our assay is based on Vero cells as hosts and infective trypomastigotes from Tulahuen
strain that express the bacterial β-galactosidase enzyme as reporter activity [21]. Firstly,
compounds were added in the first column of a 96-well tissue culture treated plates at an
initial concentration of 200, 20, or 10 µmol L−1 and diluted in assay medium following
either a 1:2 or 1:3 fold pattern to conform dose–response plate-maps. Vero cells and puri-
fied trypomastigotes were harvested, counted, and diluted to a concentration of 1 × 106
cells/mL each. Then these were mixed and 100 µL added per well (50,000 Vero cells and
50,000 trypomastigote cells per well; multiplicity of infection or MOI = 1) [56]. The reference
drug BNZ was used as control of drug growth inhibition in each run launched, whereas
each plate contained its own negative and positive control as previously described [21,56].
After 4 days at 37 ◦C, 50 µL of a PBS solution containing 0.25% NP40 and 500 µM chlorophe-
nol red-β-D-galactoside (CPRG) substrate were added per well [22]. Plates were further
incubated at 37 ◦C for another 4 h and the absorbance read out at 590 nm using an Epoch
Gene5 spectrophotometer. All experiments were performed at least in triplicate.
Additionally, based on Vero cells as hosts and the recombinant T. cruzi strain expressing
β-galactosidase, we further adapted the antiparasitic assay described above to determine
whether the activity of the compound 17-DMAG was specific against the intracellular
amastigote forms. For this, Vero cells were seeded in T-175 flasks (5 × 106 cells/flask)
in DMEM supplemented with 1% penicillin-streptomycin and 10% FBS and cultured for
24 h. Then, cells were washed once with PBS and free swimming trypomastigotes (1 × 107
trypomastigotes per flask; MOI = 1) in assay medium were added and allowed 18 h to
infect. Infected cell monolayers were washed with PBS and detached from the flasks [23].
Cells were counted and diluted to a concentration of 5 × 105 cells per mL, before adding
100 µL per well to test plates already containing the drugs as previously described. Each
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plate contained the same controls as previously described. Test plates were incubated for
72 h and their read out was performed as described above.
4.5. Cell Toxicity Assays
In this case compounds were added to tissue culture treated 96-well plates following
a dose–response dilution pattern 1:2 or 1:3 with starting concentrations of 800 µmol L−1
for dorsomorphin and 64.8 µmol L−1 for 17-DMAG. Cell viability was checked upon cell
counting with Trypan blue staining and we only proceeded if it was >95%. Vero cells were
diluted at a concentration of 5 × 105 cells per mL, before adding 100 µL per well. Each
run contained its own negative and positive controls as described. Plates were incubated
at 37 ◦C for 4 days and we used two different readout methodologies. One was based
on the traditional AlamarBlue substrate (resazurin-based), which provides a quantitative
measure of cells viability by their capacity to reduce resazurin into resorufin [40]. However,
given that inhibitors may impact cells redox state, a distorted toxicity profile could have
been obtained, and a parallel readout relying on crystal violet was also used. Vero cells
grow as monolayers, and adherent cells detach from the tissue culture plate upon cell
death. Thus crystal violet dye would only bind to structures in living cells [41]. In the
case of AlamarBlue assays, we added 50 µL per well of a PBS solution containing 10%
AlamarBlue reagent (ThermoFischer, Waltham, MA, USA) and incubated the plates for
6 h at 37 ◦C before reading the fluorescence intensity in a Tecan Infinite M Nano+ reader
(excitation: 530 nm, emission: 590 nm). In the case of crystal violet assays, cells were
washed with PBS and fixed with 100 µL of 10% formol for 15 min. Then, after washing
again we added 50 µL of a crystal violet dilution (1:5 v/v) prepared from the stock and
left it for 10 min. Crystal violet stock solution contained 250 mg of crystal violet powder
(Sigma-Aldrich), 1 mL of EtOH, and 49 mL of H2Od. After that, crystal violet excess was
eliminated washing with H2Od two times and plates were left to dry in the flow cabinet.
Finally, we added 50 µL of SDS 2% for 30 min and read out absorbance at 590 nm in an
Epoch Gene5 spectrophotometer. All experiments were performed at least in triplicate.
4.6. In Silico Study of 17-DMAG Binding to Hsp90/83 N-Terminal Domains
Hsp90 N-term domain was visualized with PyMol software (version 4.4.0) [33]. We
used PyMol as well to visualize T. cruzi Hsp83 N-term domain by means of an alignment-
directed mutagenesis upon the N-term domain of the cocrystalized human Hsp90 and
17-DMAG complex (PDB: 1OSF) [32]. We used BLAST [31] to identify the residues that
differ between human Hsp90α isoform 2 (NCBI ref.: NP_005339.3) and Hsp83 of different
T. cruzi strains. These were obtained from NCBI and TriTrypDB [57,58]. We chose T. cruzi
Hsp83 from Dm28c strain as representative (NCBI ref.: PBJ77530.1) for its visualization in
PyMol, but the same identity was shown between Hsp83 from other T. cruzi strains and
human Hsp90 (Figure S4).
We used Vina Wizard software (on PyRx-virtual screening tool) [34] to calculate the
binding affinity of 17-DMAG to Hsp90/83. The structure of 17-DMAG bound to the
N-term domain of human Hsp90 was obtained from the cocrystalized complex. On the
other hand, the N-term domain of T. cruzi Hsp83 was modeled using the SWISS-MODEL
homology-modeling tool [59] by inputting the T. cruzi Dm28c amino acid sequence. This
model was constructed based on T. brucei Hsp83 3D-structure available from the RCSB
Protein Data Bank (PDB: 3O6O). These Hsp83 proteins shared a 90% identity, which was
94% between their N-term domains.
4.7. T. cruzi Chronic In Vivo Assay
Trypomastigotes from transgenic T. cruzi Brazil strain (DTU I) expressing firefly lu-
ciferase were purified, diluted in PBS, and injected in Balb/c mice (103 trypomastigotes
per mouse) [39]. Parasites from Brazil strain have been described to be highly virulent and
susceptible to BNZ [60]. At defined time points, mice were anesthetized by inhalation of
isoflurane and injected with 150 mg/kg of D-Luciferin Potassium-salt (Goldbio, St. Louis,
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MO, USA) dissolved in PBS [35]. Mice were imaged 5–10 min after injection of luciferin
with an IVIS 100 (Xenogen, Alameda, CA, USA), and the data acquisition and analysis
were performed with the software LivingImage (Xenogen). On day 132 post-infection,
treatment was started by intraperitoneal administration of 17-DMAG at 30 mg/kg. Two
schedules of treatment were followed: one experimental group was treated daily for five
days [37]; the other was treated five times over 15 days [38]. Each group had its positive
control group which received a similar dose of 30 mg/kg of BNZ on corresponding days.
Negative control group received only vehicle solution [35]. Each group was formed by five
mice. On the scheduled days 7, 14, 23 132, 141, and 147 mice were imaged after anesthesia
and injection of luciferin as described above.
4.8. Data Analysis
Absorbance and fluorescence values respectively derived from the anti-T. cruzi and cell
toxicity assays were normalized to the controls [56]. IC50 and TC50 values were determined
with GraphPad Prism 7 software (version 7.00, 2016) using a nonlinear regression analysis
model defined by Equation (1):









IC50 and TC50 values are, respectively, defined as the compound concentration that
inhibits parasite growth by 50% or is toxic to 50% of cells. Values provided are means
and standard deviation [mean (SD)] of at least three independent experiments. Similarly,
total flux values recorded in the in vivo experiments are shown as mean and SD. We
used ANOVA with Bonferroni’s correction for multiple comparisons to determine if the
differences between groups were statistically significant.
Comparison of luciferase activity levels in T. cruzi-infected mice after treatment was
performed between days 132 (day of treatment) and days 141 (for 5 days treatment) or 147
(for 15 days intermittent treatment) by Mann–Whitney test.
5. Conclusions
Upon evaluation of nine metabolic modifier compounds we identified one with
selective anti-T. cruzi activity in the sub-micromolar range: 17-DMAG. It had potent IC50
(0.017 µmol s−1) and good SI rates (SI = 366.5 and 174.7, for the AlamarBlue and crystal
violet Vero assays, respectively). In addition, the in silico directed mutagenesis predicted
a hypothetical better binding to T. cruzi Hsp83. Regrettably, 17-DMAG did not present
parasite inhibitory activity in an in vivo chronic model of T. cruzi infection.
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